Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
Primary Objective: Injection Site Tolerability Secondary Objective: * To assess the safety profile of alirocumab SAR236553 (REGN727) * To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
Epistemonikos ID: 59f183ce2a5ddc0a1605e59776dec7c972ac02f5
First added on: May 10, 2024